CEO SUMMARY: Unilab’s desire to purchase $60 million Bio-Cypher must be viewed against the impending acquisition by Quest Diagnostics of SmithKline Beecham Clinical Laboratories (SBCL). Whenever Quest takes control of SBCL’s lab operations, it automatically becomes a significant competitor to Unilab in the Golden State. For Unilab, acquiring Bio-Cypher represents both an offensive and defensive
Subscriber-Only Content. Please Log In.
You are trying to access subscribers-only content. If you are a subscriber, please log in.
If you are not a subscriber, click here to see subscription offers.
Subscribers will have instant access to the Dark Report library, 1997-the present, giving you the most convenient, accessible archive available in laboratory business intelligence today!
To read our FREE article previews, go to The Dark Report Insider.